The conversation is about a person's 3.5-month hair regrowth progress using a combination of 8% topical minoxidil with 0.1% finasteride and 0.01% tretinoin, 5 mg oral minoxidil, and weekly use of a 1.5mm dermapen.
Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.
A user is considering mixing fast-drying minoxidil with Kirkland minoxidil to reduce greasiness and drying time. They also use liquid minoxidil to apply RU58841 powder.
The user reported progress in hair loss treatment using oral finasteride, keto 2% shampoo, and vitamin D. They experienced reduced hair fall, fewer scalp issues, and hope for improved hair density.
A user is asking if Minoboost F, a topical solution with 5% Minoxidil and 0.1% Finasteride, is effective or a scam due to the lack of online reviews. They seek opinions and reviews from others.
Hair appearance fluctuates due to factors like styling, product buildup, and humidity, causing frustration for those with diffuse thinning. Treatments mentioned include minoxidil, finasteride, ketoconazole shampoo, and RU58841, with mixed results.
A user humorously discusses the effects of using too much minoxidil, with replies joking about hair growth and treatments like oral minoxidil. The conversation includes light-hearted comments and laughter about the situation.
A user is seeking feedback on "Hair Gro" by New Nordic, which they are using alongside Rogaine, Nizoral shampoo, and castor oil for hair growth. They plan to update on their progress with the product, which contains ingredients like apple extract, millet extract, tocotrienols, tocopherol, L-Methionine, silicon, zinc, and biotin.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.
The conversation humorously discusses exaggerated eyebrow regrowth, with mentions of using minoxidil and oral minoxidil for hair growth. It includes satire and jokes about political figures and cosmetic treatments.
A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.
The conversation discusses a person's experience with hair loss treatments, including 7 months of using finasteride and minoxidil, switching to oral minoxidil, using ketoconazole shampoo, and microneedling. They notice hair regrowth more with flash photography than in regular light.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.
Oral minoxidil significantly enhances eyelash growth, with some users experiencing increased body hair. Finasteride is used alongside to manage hair thinning, with mixed results on body hair growth.
The conversation discusses the application frequency of a 1% Koshine solution for hair loss, with recommendations varying between once or twice daily. It is noted that the 1% solution is more effective than the 0.5% solution.
The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.
Using a silicone shampoo brush with ketoconazole shampoo may increase hair shedding if used roughly. Hair that sheds during shampooing would have fallen out eventually.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.
The user switched from minoxidil to a homemade 2-deoxy-d-ribose gel and noticed no hair fall after two weeks, despite stopping minoxidil. The gel includes water, 2-deoxy-d-ribose, vegetable glycerine, 2-phenoxyethanol, sodium alginate, and rosemary oil, and the user reports healthier-feeling hair.
The conversation is about a user's hair growth progress after 9 months of using oral minoxidil and finasteride, along with dermastamping. The user reports improved hair health and color, with some visible scalp remaining, and no side effects from the treatment.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.